{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T19:17:14Z","timestamp":1787253434816,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cardiac rehabilitation (CR) improves quality of life and prognosis in patients with coronary heart disease (CHD). The aim of the study was to evaluate effects of lipid-lowering therapy (LLT) in patients with CHD during and after CR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from prospective, multicenter registry including 1,100 patients with CHD undergoing CR in 6 German cardiac rehabilitation centers between 2016 and 2018 were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of statin-treated patients increased from 1,048 (96.3%) on admission to 1,062 (98.4%) at discharge (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), falling to 644 (96.3%) and 609 (94.1%) at 3 and 12 months, respectively. Combination treatment with ezetimibe was effective in 8.9% of patients at admission and 28.5% at discharge (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), and 23.5% and 25.8% after 3 month and 12 months, respectively. Titration of LLT during CR resulted in median LDL-C-values of 2.27\u2005mmol\/L at admission, 1.97\u2005mmol\/L at discharge (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), 1.94\u2005mmol\/L after 3 months, and 1.94\u2005mmol\/L after 12 months, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>During CR, LLT was effectively instituted and titrated, resulting in a high rate of statin-treated patients and a significant reduction in LDL-C. From this study, we hypothesize that CR is efficacious for adherence to LLT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1549935","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:20:22Z","timestamp":1745490022000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Lipid-lowering therapy (LLT) in 1,100 cardiac rehabilitation patients with coronary heart disease: the LLT-R(ehabilitation) registry"],"prefix":"10.3389","volume":"12","author":[{"given":"Frank","family":"Noack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Eckrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"V\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Bongarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Schwark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schlitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/2047487320913379","article-title":"Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the secondary prevention and rehabilitation section of the European association of preventive cardiology","volume":"28","author":"Ambrosetti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.atherosclerosis.2014.09.026","article-title":"Combination therapy in dyslipidemia: where are we now?","volume":"237","author":"Catapano","year":"2014","journal-title":"Atherosclerosis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby","year":"2006","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1177\/2047487320905719","article-title":"Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the cardiac rehabilitation outcome study (CROS-II)","volume":"27","author":"Salzwedel","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1161\/CIRCULATIONAHA.112.093310","article-title":"Cardiac rehabilitation 2012: advancing the field through emerging science","volume":"125","author":"Kwan","year":"2012","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3238\/arztebl.2015.0527","article-title":"Rehabilitation in patients with coronary heart disease: participation and its effect on prognosis","volume":"112","author":"Schlitt","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/2047487318817082","article-title":"Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: results of the PATIENT CARE registry","volume":"26","author":"Schwaab","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5535\/arm.2011.35.3.381","article-title":"The effect of a self exercise program in cardiac rehabilitation for patients with coronary artery disease","volume":"35","author":"Kim","year":"2011","journal-title":"Ann Rehabil Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD011273","DOI":"10.1002\/14651858.CD011273.pub2","article-title":"Cardiac rehabilitation for people with heart disease: an overview of cochrane systematic reviews","volume":"2014","author":"Anderson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pcad.2014.10.001","article-title":"Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations","volume":"57","author":"Gielen","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD001800","DOI":"10.1002\/14651858.CD001800.pub3","article-title":"Exercise-based cardiac rehabilitation for coronary heart disease","volume":"2016","author":"Anderson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1185\/03007991003604216","article-title":"Effect of early short-term cardiac rehabilitation after acute ST-elevation and non-ST-elevation myocardial infarction on 1-year mortality","volume":"26","author":"Junger","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1177\/2047487313486040","article-title":"Short-term comprehensive cardiac rehabilitation after AMI is associated with reduced 1-year mortality: results from the OMEGA study","volume":"21","author":"Rauch","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/1741826710389392","article-title":"In-patient cardiac rehabilitation versus medical care\u2014a prospective multicentre controlled 12 months follow-up in patients with coronary heart disease","volume":"18","author":"Schwaab","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"B19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2147\/VHRM.S197089","article-title":"Adherence to lipid-lowering therapy in patients with coronary heart disease from the state of Saxony-Anhalt, Germany","volume":"15","author":"Wa\u00dfmuth","year":"2019","journal-title":"Vasc Health Risk Manag"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e010376","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2013findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12872-019-1032-4","article-title":"Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cardiovasc Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12933-020-01164-8","article-title":"The DARWIN-T2D network of the Italian diabetes society. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics","volume":"19","author":"Morieri","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","article-title":"Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany","volume":"113","author":"Koenig","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.cjca.2012.03.018","article-title":"Nonadherence to statin therapy: discontinuation after a single fill","volume":"28","author":"Lemstra","year":"2012","journal-title":"Can J Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-022-01495-8","article-title":"Physicians\u2019 misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes","volume":"21","author":"Morieri","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-021-01338-y","article-title":"Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets\u2019 attainment in subjects with and without type 2 diabetes","volume":"20","author":"Morieri","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.amjcard.2014.11.026","article-title":"Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials","volume":"115","author":"Hsue","year":"2015","journal-title":"Am J Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/ph17070913","article-title":"Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review","volume":"17","author":"Zimodro","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e010685","DOI":"10.1161\/CIRCOUTCOMES.123.010685","article-title":"Association of use and dose of lipid-lowering therapy post acute myocardial infarction with 5-year survival in older adults","volume":"17","author":"Fayol","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1549935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:20:22Z","timestamp":1745490022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1549935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2025.1549935"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1549935","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"1549935"}}